Impact of Pulmonary Function Testing As Pre-Screening in Multiple Myeloma CAR-T Therapy

Puntos clave

• Improved patient outcomes were associated with earlier identification of pulmonary issues through testing, allowing for better treatment planning.
• Pulmonary function testing identified abnormalities in 45% of patients prior to CAR-T therapy, which influenced clinical decisions.
• Assessment using pulmonary function testing suggests a proactive approach to identifying risks before CAR-T therapy initiation, affecting treatment effectiveness.
• These findings imply that incorporating pulmonary function assessment may enhance safety and outcomes in CAR-T treatment for multiple myeloma.